I
n allografts, recipient leukocytes and alloantibodies attack donor endothelial cells (ECs) early in acute rejection. Cell-cell interactions among leukocytes and interactions between leukocytes and ECs or platelets critically influence immune responses. These adhesive interactions require multistep adhesive and signaling events, including selectinmediated attachment and rolling, leukocyte activation, and integrin-mediated firm adhesion and diapedesis, that result in the infiltration and accumulation of inflammatory cells into tissues. 1 Firm attachment depends on members of the ␤ 2 -integrin family, LFA-1 (␣ L␤2 , CD11a/CD18), Mac-1 (␣ M␤2 , CD11b/CD18), p150,95 (␣ M␤2 , CD11c/CD18), and CD11d/ CD18, expressed exclusively by hematopoietic cells.
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Formation of the immunological synapse requires direct interaction between T-cell integrins and cognate ligands on antigen-presenting cells (APCs). 2 LFA-1 binding to intracellular adhesion molecule-1 (ICAM-1) reduces the level of antigen required to form the immune synapse, thereby lowering B-cell activation thresholds. 3 Engagement of ICAM-1 on target cells leads to major histocompatibility complex class I (MHC-I) recruitment to contact areas and enhances presentation of cognate peptide/MHC-I complexes to cytotoxic T cells. 4 Mac-1 resides on neutrophils, monocytes, macrophages, dendritic cells, CD8 ϩ T cells, and natural killer cells. [5] [6] [7] Endothelial ligands for Mac-1 include ICAM-1, 8 -10 endothelium-associated extracellular matrix proteins (eg, fibrinogen), [11] [12] [13] CD154, 14 and glycosaminoglycans. 15 These adhesive interactions facilitate firm attachment and transmigration into interstitial tissue. 16, 17 Numerous studies have shown that the donor ECs in rejecting cardiac allografts robustly express ICAM-1 and that augmented expression of adhesion molecules precedes leukocyte accumulation within vessels. 18 -20 These results suggest that ICAM-1 induction during early rejection contributes to mononuclear cell recruitment and renders ECs more susceptible to cell-mediated injury, including graft arterial disease (GAD). 20, 21 Nevertheless, it remains unclear whether donor adhesion molecules contribute critically to allograft rejection. Treatment with monoclonal antibodies against ICAM-1 and LFA-1 resulted in indefinite cardiac allograft survival between fully histoincompatible mice strains 22 but had no effect on allograft survival in fully incompatible rat strains. 23 In 1 study, ICAM-1-deficient donor hearts did not exhibit prolonged graft survival or attenuated GAD 24 ; in another report, ICAM-1-deficient donor hearts had modest (2 to 2.5 days), albeit significantly prolonged, graft survival. 25 A definitive role for Mac-1 in allograft rejection is uncertain. Antibody targeting of Mac-1 did not affect graft survival time but decreased the accumulation of graft macrophages. 26 However, antibody experiments have several important limitations: (1) Complete blockade is difficult, particularly for those integrins with mobilizable intracellular storage pools such as Mac-1 27 ; (2) antibodies binding to the surface of leukocytes can stimulate changes in cellular functions and behavior (eg, through activation of Fc receptors when immunoglobulin G [IgG] antibodies are used); and (3) because Mac-1 associates closely with and influences other cell surface receptors such as the urokinase receptor, 28 antibody binding may cause steric interference with the associated receptor. The present study avoided these limitations of antibody administration by using a genetic approach, examining parenchymal rejection (PR) and GAD after cardiac transplantation in Mac-1 Ϫ/Ϫ recipients.
Methods

Animals
C57BL/6 (B6; H-2 b ), B6.C-H2Ͻbm12ϾKhEg (bm12; H-2 bm12 ), and BALB/c (B/c) mice were from Taconic Farms (Germantown, NY) or The Jackson Laboratory (Bar Harbor, Me). Mac-1 Ϫ/Ϫ C57BL/6 mice were kindly provided by Dr Christie M. Ballantyne (Baylor College of Medicine, Houston, Tex). 29 Mice were maintained on acidified water in barrier animal facilities. Animal care and procedures were reviewed and approved by the Harvard Medical School Standing Committee on Animals and performed in accordance with the guidelines of the American Association for Accreditation of Laboratory Animal Care and the National Institutes of Health.
Vascularized Heterotopic Cardiac Transplantation
B/c (total allomismatch to assess effects on acute rejection) or bm12 (MHC-II mismatch to assess effects on GAD) donor hearts were transplanted heterotopically into B6 recipients without immunosuppression. 30 We assessed graft function by palpation twice daily. In total allomismatched experiments, 2 cohorts of wild-type (WT) and Mac-1 Ϫ/Ϫ recipients were used. The first group of animals served to determine graft survival, defined as the day of cessation of beating or when the strength of beating declined to the point that failure would occur (by prior experience) within the next 12 hours. In the second group of animals, beating cardiac allografts were harvested at the prespecified time point of 7 days after transplantation. For single MHC-II-mismatched transplantation, grafts were harvested at 4 and 12 weeks.
PR and the severity and extent of GAD were quantified with a 4-point scoring system by blinded observers as described previously. 30 PR was scored on a scale of 0 to 4 (0, no rejection; 1, focal mononuclear cell infiltrates; 2, focal mononuclear infiltrates with necrosis; 3, multifocal infiltrates with necrosis; and 4, widespread infiltrates with hemorrhage and/or vasculitis); GAD was scored on a scale of 0 to 4 on the basis of the extent of luminal stenoses averaged over Ն10 arteries (0, Ͻ10%; 1, Ͻ10% to 25%; 2, 25% to 50%; 3, 50% to 75%; and 4, Ͼ75% stenosis).
Graft Harvest
Harvested allografts were transversely sectioned into 3 parts. In sectioned hearts, the most basal part was used for routine hematoxylin and eosin morphological examination. A second midtransverse section was frozen for immunohistochemical staining, and the apical portion was used for total RNA extraction for RNase protection assay. 30 For cellular extraction, hearts were digested at 37°C in 2 mg/mL collagenase (Sigma, St Louis, Mo) and 2% BSA in buffered saline, followed by straining and Ficoll density gradient centrifugation (Organon Teknika, West Chester, Pa). 30 
Immunohistochemistry
Cryosections (5 m) were fixed in acetone before incubation with 0.5% H 2 O 2 . Slides were incubated with 10% normal goat serum and stained with purified monoclonal anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-Mac-3 (macrophage), or anti-Gr-1 (neutrophil, RB6-8C5) antibodies. Sections were incubated with biotinylated goat anti-rat IgG antibodies (1 g/mL, Southern Biotechnology Associates, Inc, Birmingham, Ala), followed by streptavidin-peroxidase (Dako, Glostrup, Denmark). Antibody binding was visualized with 3-amino-9-ethyl carbazole (Dako). Nuclei were counterstained with Gill's hematoxylin (Sigma).
Mixed Lymphocyte Reaction, T-Cell Proliferation Assay, and Cytokine ELISA
One-way mixed lymphocyte reaction (MLR) was performed as described previously 30 with irradiated B/c splenocytes as stimulators and B6 splenocytes as responders. T-cell or B-cell proliferation assay was performed with anti-CD3 antibody-coated 96-well plates or by adding anti-CD40 monoclonal antibodies (3/23, BD PharMingen, San Diego, Calif).
We also performed MLR using allograft-derived macrophages as stimulators and naive B6 T cells as responders. We isolated macrophages from the allografts of B6 WT or B6 Mac-1 Ϫ/Ϫ recipients 7 days after transplantation as described previously. 30 We extracted T cells from naive B6 WT splenocytes using MACS beads (Miltenyi Biotec Inc, Auburn, Calif) with negative selection according to the manufacturer's methods. We plated irradiated allograft-derived macrophages (50 000 cells per well) and naive B6 T cells (500 000 cells per well, S:Rϭ1:10) in the 96-well plates and measured T-cell proliferation using 3 H-thymidine incorporation. 30 We also measured tumor necrosis factor-␣ (TNF-␣) levels in the supernatant of the coculture by ELISA as described previously 30 using purified anti-TNF-␣ and biotinylated anti-TNF-␣ monoclonal antibodies (BD PharMingen).
Total RNA Extraction and RNase Protection Assay
Total RNA was isolated from allografts with the TRIzol reagent (Invitrogen, Carlsbad, Calif). RNase protection assay was performed (RiboQuant, PharMingen) with 10 g RNA from each heart according to the manufacturer's recommendations. 30 
Murine Peritoneal Macrophage and Bone Marrow Neutrophil Isolation
Peritoneal cells were collected via peritoneal lavage using 10 mL ice-cold RPMI 1640. Lavage cells were pelleted, resuspended in 5 mL hypertonic RBC lysis buffer (ACK lysing buffer, Invitrogen) at 37°C for 5 minutes, washed with RPMI 1640 twice, and resuspended in 5 mL RPMI 1640. Cells were centrifuged in Percoll gradient solution for 30 minutes. 31 Cells in the upper layer were resuspended in 10% FCS RPMI 1640, plated on plastic dishes for 60 minutes, and washed twice to remove nonadherent cells, resulting in Ͼ95% pure macrophages, confirmed by Mac-3 staining and flow cytometry. To isolate neutrophils from the bone marrow, we removed the femur and tibia from both hind legs and cut off the extreme distal tip of each extremity. RPMI 1640 medium was forced through the bone with a syringe. After dispersing cell clumps and erythrolysis, the cell suspension was centrifuged (400g for 10 minutes at 4°C) and resuspended in 1 mL RPMI 1640. Cells were then treated on a 3-layer Percoll gradient exactly as described above for peritoneal cells. Flow cytometry using anti-Ly-6G and Gr-1 antibodies showed Ͼ95% purity of neutrophils.
Murine EC Isolation and Coculture With Macrophages
ECs were isolated from the B/c murine hearts as described previously 32 and incubated for 72 hours with the peritoneal macrophages extracted from naive B6 WT or Mac-1 Ϫ/Ϫ mice. We performed flow cytometry analysis for costimulatory molecule expression of the B/c EC-primed macrophages as described below.
Cellular Surface Staining and Flow Cytometric Analysis
Graft-infiltrating cells and B/c-EC-primed macrophages were analyzed by flow cytometry after surface staining using methods described previously. 30 Antibodies included anti-MHC-II phycoerythrin (PE) (I-A/I-E, M5/114.15.2), anti-CD40-PE, anti-CD86-PE, or anti-ICOSL-PE antibodies; PE-conjugated rat IgG2b (negative control, PharMingen); or anti-CD80-PE and PE-conjugated hamster IgG (negative control). Anti-MAC-3 antibody was used for macrophage staining.
Statistical Analysis of the Graft Survival and Cell Number, Proliferation, and Cytokine Production
Comparisons between the 2 groups for graft survival used KaplanMeier and log-rank tests; frequency of graft-infiltrating cells, cell proliferation, and ELISA used 1-way ANOVA. We described PR and GAD scores as meanϮSD and analyzed them by Fisher exact test using the GraphPad Prism 4 software for Macintosh (GraphPad Software, San Diego, Calif).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Deficiency of Recipient Mac-1 Attenuates PR and Prolongs Graft Survival in Total Allomismatched Allografts
In total allomismatched murine cardiac allografts (B/c donor hearts and B6 recipients), survival averaged 13.8Ϯ2.3 days (meanϮSD; nϭ6) for allografts in Mac-1 Ϫ/Ϫ recipients compared with 8.3Ϯ1.3 days (nϭ18) in WT recipients ( Figure  1A ). Failing grafts in WT recipients showed severe coronary arteritis with perivascular edema and confluent areas of myocardial necrosis 7 days after transplantation. In comparison, at the same time point, grafts in Mac-1 Ϫ/Ϫ recipients exhibited virtually no arterial inflammation, edema, or coagulative necrosis, despite the presence of multifocal parenchymal inflammatory infiltrates ( Figure 1B ). Reflecting these differences, the PR scores were significantly lower for allografts in Mac-1 Ϫ/Ϫ recipients 7 days after transplantation (2.3Ϯ0.4, meanϮSD; nϭ6) compared with WT recipients (3.0Ϯ0.4; nϭ13; Pϭ0.0408). At this 7-day time point, inflammatory cells and thrombi populated vessel luminal areas in allografts of WT recipients. These lesions differ from chronic GAD lesions that consist predominantly of smooth muscle-like cells. 33 Nevertheless, we scored the extent of early luminal occlusion using the GAD scoring system. Scores were significantly lower for grafts in Mac-1 Ϫ/Ϫ (0.01Ϯ0.02, meanϮSD; nϭ6) compared with WT (0.63Ϯ0.44; nϭ13; Pϭ0.0108) recipients ( Figure 1C) . Thus, deficiency of recipient Mac-1 prolongs allograft survival and is associated with diminished inflammatory cell accumulation, including reduced luminal inflammatory cells. At the time of eventual graft failure in Mac-1 Ϫ/Ϫ recipients (13.8Ϯ2.3 days), PR scores were 3.2Ϯ0.9, with luminal stenosis graded at 1.3Ϯ1.1.
Mac-1 Deficiency Reduces the Intragraft Accumulation of Neutrophils, CD8 ؉ T Lymphocytes, and Macrophages
Immunohistochemical analysis examined the characteristics of the immune cell infiltration in transplanted hearts in WT and Mac-1 Ϫ/Ϫ recipients 7 days after allografting. Anti-Gr-1 identified neutrophils, anti-CD4 or anti-CD8 for T cells, and anti-Mac-3 for macrophages. Neutrophil (Gr-1-positive cells), CD8
ϩ T cell, and macrophage (Mac-3-positive cells) accumulation all decreased significantly in Mac-1 Ϫ/Ϫ compared with WT recipients. The transplanted hearts of both Mac-1 Ϫ/Ϫ and WT recipients had comparable numbers of CD4 ϩ T cells (Figure 2A and 2B). To verify that differences in leukocyte recruitment in Mac-1 Ϫ/Ϫ mice were not secondary to differences in peripheral blood leukocyte counts, we performed complete blood count analysis in WT Figure 3B ). PR scores of allografts also increased significantly in Mac-1 Ϫ/Ϫ recipients receiving WT (2.3Ϯ0.4; meanϮSD; nϭ6) versus Mac-1 Ϫ/Ϫ (1.5Ϯ0.5; nϭ5; Pϭ0.024) macrophages ( Figure 3C ). These observations indicate that macrophages expressing Mac-1 participate in graft inflammatory cell accumulation and influence graft survival in total allomismatched allografts.
Lack of Mac-1 Reduced Early PR and GAD but Not Chronic GAD in MHC-II-Mismatched Cardiac Transplantations
We examined PR and GAD after MHC-II-mismatched murine heart transplantation using bm12 donor hearts and WT or Mac-1 
Mac-1 ؊/؊ Splenocytes Have Attenuated MLR but Normal Responses to Anti-CD3 and Anti-CD40 Antibodies
Interaction of APCs and T cells, as well as the subsequent strength of the alloresponse, may affect cellular recruitment. 36 Mac-1 also can directly limit T-cell and/or dendritic cell function and may alter the local cytokine milieu. 5, 6, 37 Therefore, we examined whether Mac-1 deficiency modulates MLR using WT or Mac To examine whether Mac-1-deficient splenocytes ineffectively prime T cells, we performed B/c-primed MLR. B/cprimed splenocytes from WT or Mac-1 Ϫ/Ϫ recipients of B/c cardiac allografts were recovered 6 days after transplantation and were stimulated with or without (control) irradiated naive B/c splenocytes. Interestingly, splenocytes harvested from Mac-1 Ϫ/Ϫ transplant recipients showed significantly less proliferation compared with splenocytes recovered from WT recipients ( Figure 6D ). The results suggest that Mac-1 Ϫ/Ϫ splenocytes lead to ineffective T-cell priming in vivo.
Mac-1 ؊/؊ Macrophages Express Reduced Levels of Costimulatory Molecules and Have Diminished Alloantigen-Presenting Function
Macrophages make up most of inflammatory cells at the later phases of acute rejection. 30, 38 Macrophages can exhibit direct cytotoxicity against certain cells 39 and can function in allograft rejection as APCs. 40 We tested the hypothesis that intragraft Mac-1 Ϫ/Ϫ macrophages have impaired activation and exhibit reduced antigen-presenting function compared with WT macrophages. To do so, immune cells were extracted from cardiac allografts harvested from WT and Mac-1 Ϫ/Ϫ recipients 6 days after transplantation; flow cytometry was performed to assess macrophage MHC-II and costimulatory molecule expression. Graft macrophages in Mac-1 Ϫ/Ϫ recipients showed significantly lower expression of CD40, CD80, CD86, ICOSL, and MHC-II compared with those in WT recipients ( Figure 7A and 7B) .
We also used the macrophages extracted from B/c allografts of B6 WT or Mac-1 Ϫ/Ϫ recipients as a stimulator of B6 naive T cells and performed primed MLR (primed macrophages as stimulator and naive T cells as responder). The results demonstrated that naive T cells stimulated by the primed macrophages extracted from the allografts of Mac-1 Ϫ/Ϫ recipients had a lower proliferative capacity ( Figure 7C ) and secreted less TNF-␣ ( Figure 7D ) compared with those stimulated by the primed macrophages extracted from the allografts of WT recipients. These results suggested that Mac-1 Ϫ/Ϫ macrophages have lower antigen-presenting capacity.
Because recipient leukocytes first encounter donor ECs after transplantation, the ability of donor ECs to facilitate antigen presentation probably is important. Thus, to assess 
Discussion
The present study provides in vivo evidence that Mac-1 promotes acute allograft rejection. Recipient Mac-1 deficiency reduced allograft accumulation of immune cells, prolonged allograft survival, but did not prevent GAD. The 
Possible Mechanism of Mac-1 Action in Acute Rejection
Mac-1 localizes on neutrophils, monocytes, macrophages, natural killer cells, and CD8 ϩ T cells. 5, 7 The functional relevance of ␤ 2 -integrins such as Mac-1 (CD11b/CD18) on APCs remains unclear. Varga and coworkers 41 reported recently that Mac-1 on APCs, including dendritic cells and macrophages, directly inhibited T-cell activation. In that study, CD18
Ϫ/Ϫ macrophages stimulate allogeneic T cells more potently than their WT counterparts. However, Mac-1 Ϫ/Ϫ (CD11b Ϫ/Ϫ ) APCs were not examined, thereby precluding definitive conclusions on the precise role of Mac-1 given the possible contributions of other ␤ 2 -integrins, including LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/ CD18, to immune synapse function.
In contrast, the present work shows unambiguously that Mac-1 Ϫ/Ϫ macrophages have defective APC function. Direct T-cell receptor stimulation by anti-CD3 antibodies and direct B-cell stimulation with anti-CD40 antibodies induced comparable proliferation from WT and Mac-1 Ϫ/Ϫ splenocytes, indicating that Mac-1 Ϫ/Ϫ T and B cells have normal T-and B-cell receptor responses. At the same time, graft-infiltrating macrophages in Mac-1 Ϫ/Ϫ recipients and Mac-1 Ϫ/Ϫ macrophages cocultured with allo-ECs express significantly lower levels of costimulatory molecules and MHC-II compared with WT macrophages. Mac-1 Ϫ/Ϫ macrophages also stimulated T-cell proliferation more poorly than WT macrophages. Over all, our data suggest that the diminished APC function of Mac-1 Ϫ/Ϫ macrophages may prolong allograft survival by reducing T-cell priming but may do so by reducing TNF-␣ expression.
Mac-1 and GAD
By virtue of binding diverse ligands such as fibrinogen, 42, 43 ICAM-1, 44 factor X, 45 C3bi, 42 platelet glycoprotein Ib␣, 46, 47 CD154, 14 and JAM-3, 48 Mac-1 potentially regulates important leukocyte functions relevant to vascular injury, including adhesion, migration, coagulation, proteolysis, phagocytosis, oxidative burst, and signaling. 29,31,49 -52 Our prior report identified Mac-1 as a molecular determinant of neointimal thickening after endothelium-denuding injury; selective absence of Mac-1 impaired transplatelet leukocyte migration into the vessel wall, diminishing medial leukocyte accumulation and neointimal thickening after experimental angioplasty. 34 In the present study, deficiency of Mac-1 attenuated allograft leukocyte accumulation and rejection but had no effect on neointimal thickening in GAD at 12 weeks. These discrepant effects on neointimal thickening likely reflect a distinct cell recruitment mechanism provoked by mechanical arterial injury (ie, platelet-dependent neutrophil recruitment mediated in part by integrin interactions between neutrophil Mac-1 and platelet glycoprotein Ib␣) compared with the pathways downstream of immunological injury involving intact, activated endothelium (ie, endothelium-dependent mononuclear cell recruitment mediated by mononuclear ␤ 1 -and ␤ 2 -integrins and endothelial ICAM-1 and vascular cell adhesion molecule-1). Similar to GAD, deficiency of Mac-1 has no effect on high-fat-diet-induced atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. 53 
Clinical Implications
Allograft rejection, both cellular and antibody mediated, remains a clinically important limitation to human cardiac transplantation. More than 40% of patients will experience an episode of rejection in the first year after transplant that requires therapy; the average patient will experience close to 2 episodes of rejection in the first year. 54 Severe rejection episodes can cause heart failure, malignant arrhythmias, and sudden cardiac death. Higher grades of rejection (International Society for Heart and Lung Transplantation grade 3 or 4) portend poor outcomes. 54 Current treatment strategies often resolve the acute episode effectively and typically include the use of augmented doses of glucocorticoids or calcineurin inhibitors, cytolytic agents such as OKT3, and plasmapheresis. However, they are limited by the inherent toxicities of immunosuppression, including fatal infections, aggressive malignancies, and renal failure. Furthermore, antibody-mediated rejection, in particular, has no consensus treatment to date. 55 Novel therapies are greatly needed not only to decrease the morbidity of conventional immunosuppression but also to improve the outcomes of patients with specific forms of allograft rejection, especially acute antibody-mediated rejection. Although deficiency of Mac-1 did not prevent chronic rejection in our study, targeting Mac-1 is an attractive strategy to modulate acute rejection after cardiac transplantation. Indeed, previous clinical trials demonstrated improved renal allograft survival in high-risk patients (either highly immunized or retransplant recipients) who received a monoclonal antibody to one of the Mac-1 cognate ligands, ICAM-1. 56 
Study Limitations
We examined the effect of Mac-1 deficiency on PR and GAD after MHC-II-mismatched murine heart transplantation without background immunosuppression. Clinical application requires future studies evaluating the effect of Mac-1 deficiency and immunosuppressive therapy, alone or in combination, on rejection scores and GAD.
Mac-1 deficiency may affect the development and function of immune cells. The present experiments using adoptive transfer of normal cells provide compelling evidence for the importance of macrophage Mac-1 in acute rejection. Nonetheless, we cannot rule out an additional role of Mac-1 in the development and function of immune cells.
Conclusion
This study demonstrates that recipient Mac-1 deficiency reduces accumulation of graft-infiltrating cells, macrophage APC function, T-cell proliferation, and TNF-␣ production and attenuates acute allograft rejection.
